Mai Capital Management Sangamo Therapeutics, Inc Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Mai Capital Management holds 100 shares of SGMO stock, worth $117. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$117% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SGMO
# of Institutions
134Shares Held
52.5MCall Options Held
1.02MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA9.37MShares$11 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.23MShares$10.8 Million0.05% of portfolio
-
State Street Corp Boston, MA5.02MShares$5.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$5.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.08MShares$3.61 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $183M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...